ALT5 Sigma (NASDAQ:AIFC – Get Free Report) issued its earnings results on Monday. The company reported $0.42 earnings per share (EPS) for the quarter, Zacks reports. ALT5 Sigma had a negative net margin of 2,483.94% and a negative return on equity of 68.25%.
ALT5 Sigma Price Performance
ALT5 Sigma stock opened at $0.42 on Tuesday. ALT5 Sigma has a 12 month low of $0.36 and a 12 month high of $8.74. The business’s fifty day simple moving average is $0.53 and its two-hundred day simple moving average is $0.96. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.82 and a quick ratio of 0.82.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ALT5 Sigma in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ALT5 Sigma currently has an average rating of “Sell”.
Hedge Funds Weigh In On ALT5 Sigma
Institutional investors and hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. bought a new position in ALT5 Sigma in the 3rd quarter worth about $33,000. Schonfeld Strategic Advisors LLC bought a new stake in ALT5 Sigma during the 3rd quarter valued at about $45,000. Bridgeway Capital Management LLC increased its stake in ALT5 Sigma by 9.4% during the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after purchasing an additional 1,661 shares in the last quarter. Raymond James Financial Inc. raised its holdings in ALT5 Sigma by 39,884.0% in the third quarter. Raymond James Financial Inc. now owns 19,992 shares of the company’s stock worth $54,000 after buying an additional 19,942 shares during the last quarter. Finally, SIH Partners LLLP purchased a new position in ALT5 Sigma in the third quarter worth about $54,000. 6.27% of the stock is currently owned by institutional investors.
About ALT5 Sigma
ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
Featured Stories
- Five stocks we like better than ALT5 Sigma
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for ALT5 Sigma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALT5 Sigma and related companies with MarketBeat.com's FREE daily email newsletter.
